1 5 m a r c h 2 0 1 8 | V O L 5 5 5 | N a T U r E | 3 7 1 LETTEr Analysis of molecular aberrations across multiple cancer types, known as pan-cancer analysis, identifies commonalities and differences in key biological processes that are dysregulated in cancer cells from diverse lineages. Pan-cancer analyses have been performed for adult 1-4 but not paediatric cancers, which commonly occur in developing mesodermic rather than adult epithelial tissues 5 . Here we present a pan-cancer study of somatic alterations, including single nucleotide variants, small insertions or deletions, structural variations, copy number alterations, gene fusions and internal tandem duplications in 1,699 paediatric leukaemias and solid tumours across six histotypes, with whole-genome, whole-exome and transcriptome sequencing data processed under a uniform analytical framework. We report 142 driver genes in paediatric cancers, of which only 45% match those found in adult pan-cancer studies; copy number alterations and structural variants constituted the majority (62%) of events. Eleven genome-wide mutational signatures were identified, including one attributed to ultravioletlight exposure in eight aneuploid leukaemias. Transcription of the mutant allele was detectable for 34% of protein-coding mutations, and 20% exhibited allele-specific expression. These data provide a comprehensive genomic architecture for paediatric cancers and emphasize the need for paediatric cancer-specific development of precision therapies.
Signatures T-1 and T-4 (clock-like endogenous mutational processes) were present in all samples and contributed to large proportions of all mutations in T-ALL (97%), AML (63%), B-ALL (36%), and Wilms tumours (28%). T-2 and T-7 (APOBEC (apolipoprotein B mRNA editing enzyme, catalytic polypeptide-like)) were highly enriched in B-ALLs with ETV6-RUNX1 fusions (15-fold and 9-fold enrichment for T-2 and T-7, respectively; Supplementary Table 1e ). T-3 (homologous recombination deficiency) was present in many childhood cancers, including osteosarcomas (18 of 19), NBLs (59 of 137), Wilms tumours (28 of 81), and B-ALL (47 of 218). T-8 (8-oxoguanine DNA damage) was present in a small proportion (4.5-12%) of AML, B-ALL, osteosarcoma, and Wilms tumour samples. T-8 was also present in many (36%) NBL samples and was associated with age at diagnosis ( Supplementary  Table 1d ). T-9 (DNA repair deficiency) was present in two B-ALLs, including one (sample PARJSR) with a somatic MSH6 frameshift mutation. T-2, T-3, T-5, T-7, T-8, and T-9 were enriched among the 39 samples with elevated mutation rates in each histotype (Fig. 1d ).
The T-5 ultraviolet-light (UV)-exposure signature was unexpectedly present in eight B-ALL samples (Extended Data Fig. 2a-c) . Although its mutation rate in B-ALL, ranging from 0.06 to 0.72 per Mb, was 100fold lower than the average rate in adult (15.8 per Mb) 8 and paediatric (14.4 per Mb) 9 skin cancer, T-5 exhibited other features associated with UV-related DNA damage. Specifically, CC> TT dinucleotide mutations were enriched 110-fold in these eight B-ALL samples when compared with other samples (P = 1.07 × 10 −7 ), which is consistent with pyrimidine dimer formation. Moreover, transcriptional strand bias in T-5 indicated that photodimer formation contributed to cytosine damage. The validity of T-5 was further confirmed by analysis of the mutation clonality, cross-platform concordance, genomic distribution and mutation spectrum of each sample (see Methods, Extended Data Fig.  2d -i), indicating that UV exposure or other mutational processes 10, 11 may contribute to paediatric leukemogenesis. Notably, all T-5 B-ALLs had aneuploid genomes (P = 3 × 10 −5 ; two-sided binomial test; cohort frequency 24%) without any oncogenic fusions.
By analysing the enrichment 12, 13 of somatic alterations within each histotype or the pan-cancer cohort (see Methods), we identified 142 significantly mutated driver genes ( Fig. 2a , Supplementary Table 2 , Extended Data Fig. 3a ). Somatic alterations in CDKN2A, which were predominantly deletions, occurred at the highest frequency, affecting Letter reSeArCH 207 of 267 (78%) T-ALLs, 91 of 218 (42%) B-ALLs and 2 of 19 (11%) osteosarcomas (Extended Data Fig. 3b ). More than half (73) of the driver genes were specific to a single histotype, such as TAL1 for T-ALL and ALK for NBL (Extended Data Fig. 3c ). Genes that were mutated in both leukaemias and the three solid tumour histotypes accounted for only 17% of driver genes (Extended Data Fig. 3e ), of which some genes had various types of somatic alteration. For example, STAG2, a known driver gene for Ewing's sarcoma 14 and adult AML 15 , exhibited five different types of somatic alteration (single nucleotide variants (SNVs), small insertions or deletions (indels), copy number alterations (CNAs), structural variants and internal tandem duplications (ITDs)) across five histotypes (Extended Data Fig. 4a-d ). Nine STAG2 variants were predicted to cause protein truncation, including four predicted by aberrant transcripts in RNA sequencing (RNA-seq). Notably, 78 of 142 driver genes (Supplementary Table 2 ) were not found in adult pancancer studies [1] [2] [3] [4] , and 43 ( Fig. 2a and Extended Data Fig. 3a) were not found in the Cancer Gene Census (v81) 16 . Thirty-seven were absent from both sources, although mutations in cancer have been reported for 29 of these genes, such as NIPBL [17] [18] [19] and LEMD3 20 (Extended Data Fig. 4p , q). Nearly half (40-50%) of point mutations in leukaemia and NBL driver genes had low MAFs (< 0.3), indicative of subclonal mutations contributing to tumorigenesis (Extended Data Fig. 3f ).
Three hundred and four gene-pairs exhibited statistically significant (P < 0.05, two-sided Fisher's exact test; Fig. 2b , Supplementary Table 3 ) co-occurrence (for example, USP7 and TAL1 in T-ALL 21 ) or mutual exclusivity (for example, MYCN and ATRX in NBL 22 ). The analysis also unveiled novel co-occurrences (for example, ETV6 and IKZF1 in AML and CREBBP and EP300 in B-ALL) and mutual exclusivities (for example, SHANK2 and MYCN in NBL and PAX5 and TP53 in B-ALL).
Because of reduced power for detecting low-frequency drivers 2 (detection limits were 1% for the entire cohort and 3% for individual histotypes with more than 200 samples; Extended Data Fig. 5 and Methods), we performed subnetwork analyses 3 and variant pathogenicity classification 23 (see Methods), identifying 184 variants in 82 additional genes (Supplementary Table 4 and Extended Data Fig. 4e , f). A notable example is the MAP3K4 G1366R mutation, which was found in one T-ALL, two B-ALLs, and one Wilms tumour. MAP3K4 is a member of the MAPK family 24 and structural modelling indicates that the G1366R mutation is likely to cause disruption of normal inhibitory domain binding and kinase dynamics 24 (Extended Data Fig. 4l, m) . Several genes in which structural variants were found (PDGFRA, CDK4, YAP1, UBTF) are listed in Extended Data Fig. 4 .
While the percentage of tumours with point mutations in driver genes was highly consistent between whole-genome sequencing (WGS) and whole-exome sequencing (WES) ( Fig. 3a) , WGS makes it possible to detect CNAs and structural variants, which are frequently driver events for paediatric cancers. For example, 72% of NBL tumours analysed by WGS had at least one driver variant compared to 26% of those analysed by WES ( Fig. 3a and Extended Data Fig. 4j , k). Furthermore, integrative analyses of CNAs and structural variants with WGS data revealed chromothripsis (that is, massive rearrangements caused by a single catastrophic event) in 11% of all samples (13 in osteosarcomas, 15 in Wilms tumours, 22 in NBL, 14 in B-ALL, and 6 in AML; Extended Data Fig. 1f ). We next performed pathway analyses (see Methods) on 654 samples analysed by WGS and 264 T-ALL samples analysed by both WES and single nucleotide polymorphism (SNP) arrays, totaling 682 leukaemias and 236 solid tumours.
The 21 biological pathways that were disrupted by driver alterations were either common (for example, cell cycle and epigenetic regulation) 
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or histotype-specific (for example, JAK-STAT, Wnt/β -catenin, and NOTCH signalling) ( Fig. 3b ). More importantly, the genes that were mutated in each pathway differed between histotypes. One example is signalling pathways such as RAS, JAK-STAT and PI3K ( Fig. 3c ).
For genes in these pathways, somatic alterations in solid tumours primarily occurred in ALK, NF1, and PTEN, whereas nearly all mutations in FLT3, PIK3CA, PIK3R1, and RAS were found in leukaemias. Although many biological processes are dysregulated in both paediatric and adult cancers 1, 2, 4 , the affected genes may be either paediatric-specific (for example, transcription factors and JAK-STAT pathway genes) or common to both (for example, cell cycle genes and epigenetic modifiers). Notably, two novel KRAS isoforms were detected in 70% of leukaemias but rarely in solid tumours (Extended Data Fig. 6 ). Evaluation of mutant allele expression makes it possible to assess the effects on the gene product and to detect potential epigenetic regu lation that may cause allelic imbalance. Here we present this analysis on 6,959 coding mutations with matching WGS and RNA-seq data. RNA-seq expression clusters confirmed the tissue of origin of each histotype (Extended Data Fig. 7 ). Mutant alleles were expressed for 34% of these mutations, which is consistent with previous reports [25] [26] [27] . The expression of mutant alleles is generally associated with corresponding DNA MAF and the expression levels of host genes (Fig. 4a) ; however, exceptions can be found due to X-inactivation, imprinting, nonsense-mediated decay or complex structural re-arrangements (Extended Data Fig. 8a ).
Allele-specific expression (ASE) was evaluated for 2,477 somatic point mutations with sufficient read-depth in DNA and RNA-seq (see Methods). Of 486 candidate ASE mutations ( Supplementary Table 5 ), 279 had no detectable expression of the mutant allele, and a comparable DNA MAF distribution was found for truncating and non-truncating mutations (P = 0.5, two-sided Wilcoxon rank-sum test, Extended Data Fig. 8b ). Of the remaining 207 candidate ASE mutations, 76% of truncating mutations exhibited suppression of the mutant allele (P = 7 × 10 −5 ; two-sided binomial test), while 87% of hotspot mutations showed the opposite trend of elevated expression (P = 6 × 10 −5 ; two-sided binomial test; Fig. 4b , Extended Data Fig. 8c ). Excluding hotspot mutations resulted in equal distribution of suppression versus elevation (66 versus 55) for the remaining 121 non-truncating ASE mutations (P = 0.4; two-sided binomial test).
Subclonal loss-of-heterozygosity (LOH) in tumours is a confounding factor for ASE analysis. For example, significant allelic imbalance between tumour DNA and RNA MAF of WT1 D447N in an AML that also harboured a subclonal 11p copy-neutral LOH (Fig. 4c ) could be attributed to ASE or WT1 expression of a subclone with a double-hit of D447N mutation and 11p LOH. To address this, we performed single-cell DNA sequencing on 63 germline variants on 11p and the somatic point mutations. We confirmed ASE by establishing that WT1 D447N and 11p LOH occurred in separate subclones ( Fig. 4c and Extended Data Fig. 9a, b ). The resulting genotype data projected that one WT1 allele was silenced in a common ancestor and the other was lost in the three descendant subclones by 11p LOH, acquisition of the WT1 D447N mutation, or focal deletion. Two additional AMLs with WT1 D447N also exhibited ASE (Extended Data Fig. 9c ), implying that loss of WT1 expression by epigenetic silencing or mutations in cis-regulatory elements is not rare in AML. Similarly, single-cell sequencing of an ALL sample confirmed ASE of a JAK2 hotspot mutation (Extended Data Fig. 9d ).
The somatic variants used for this study are available at the National Cancer Institute TARGET Data Matrix and our ProteinPaint 28 portal, which provides an interactive heat map viewer for exploring mutations, genes, and pathways across the six histotypes (Extended Data Fig. 10 ). The portal also hosts the somatic variants analysed by the companion paediatric pan-cancer study of 961 tumours from 24 histotypes, including 559 central nervous system tumours 29 . We anticipate that these complementary pan-cancer datasets will be an important resource for investigations of functional validation and implementation of clinical genomics for paediatric cancers. For T-ALL, CNAs were derived from SNP array. b, Percentage of tumours within each histotype that have somatic alterations in 21 biological pathways; histotype ordering is as in a.
The coloured portion of each pathway indicates the percentage of variants in genes that are absent in three TCGA pan-cancer studies. c, Mutation occurrence by histotype in RAS, tyrosine kinase, and PI3K pathways. Author Information Reprints and permissions information is available at www.nature.com/reprints. The authors declare no competing financial interests. Readers are welcome to comment on the online version of the paper. Publisher's note: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations. Correspondence and requests for materials should be addressed to J.Z. (jinghui.zhang@stjude.org). In our cohort, osteosarcoma has a higher percentage of older patients because the age of onset has a bimodal distribution: the first peak occurs among adolescents and young adults, and the second (associated with Paget disease and with a different underlying biology 30 ) occurs among the elderly. We used an age cutoff of 40 years, which is typical for COG-conducted osteosarcoma trials 31 . Informed consent was obtained from all subjects. Genomic datasets. WGS, WES, and RNA-seq data were downloaded from dbGaP with study identifier phs000218 (including phs000463, phs000464, phs000465, phs000467, phs000471, and phs000468). Among the 1,699 cases analysed, 45 B-ALLs 32,33 , 197 AMLs 34 , 264 T-ALLs 21 , 240 NBLs 35 and 115 Wilms tumours 36 have been included in published studies of individual histotypes. No statistical methods were used to predetermine sample size. The experiments were not randomized. The investigators were not blinded to allocation during experiments and outcome assessment. WGS data analysis. WGS data were generated with Complete Genomics Inc. (CGI) technology with an average genome-wide coverage of 50× using 31-to 35-bp mate-paired reads, which was powered for detecting mutations in 94% of mappable exonic regions 37, 38 . Read pairs were mapped to hg19/GRCh37, and somatic SNVs, indels, and structural variants were analysed by comparing paired tumour and normal genomes using the CGI Cancer Sequencing service pipeline version 2 38, 39 .
For each case, we downloaded CGI-generated WGS files for somatic SNVs, indels, structural variants, and CNAs from the TARGET Data Matrix as the starting point for our analysis. Filtering of point mutations. Putative somatic point mutations including SNVs and indels were extracted from Mutation Annotation Format files and run through a filter to remove false-positive calls. First, germline variants were filtered by using: (1) NLHBI Exome Sequencing Project (http://evs.gs.washington.edu/EVS/); (2) dbSNP (build 132); (3) St Jude/Washington University Paediatric Cancer Genome Project (PCGP); and (4) germline variants present in five or more TARGET CGI WGS cases in each cohort. Second, a variant was removed unless it met the following criteria: (1) at least three reads supported the mutant allele in the tumour; (2) the mutant read count in the tumour was significantly higher than normal (P < 0.01 by two-sided Fisher's exact test); and (3) the normal MAF was below 0.05. Finally, a BLAT search 40 was run on the mutant allele with 20-bp flanking to verify unique mapping.
A 'rescue' pipeline was implemented to avoid over-filtering, by using the customized AnnoVar annotation and pathogenicity identification tool Medal_ Ceremony 23 (M.N.E. et al., unpublished). Pathogenic variants were rescued and further curated with ProteinPaint 28 .
This filtering has reduced the original 51 million SNVs and 38 million indels from the CGI files to a set of 711,490 SNVs and 57,700 indels. Of these, 9,397 SNVs and 1,000 indels are in protein coding regions. A comparison with gnomAD database (version r2.0.1; http://gnomad.broadinstitute.org/) indicated that 1.1% of our detected SNVs overlap with SNPs with population frequency greater than 0.1%. Verification of somatic point mutations after filtering is presented in Supplementary Note 1. Filtering of structural variation. CGI structural variants were filtered to remove germline rearrangements, including those found in the Database of Genomic Variants, dbSNP, PCGP, recurrent germline rearrangements from CGI Mutation Annotation Format files, low-confidence somatic calls (> 90% reference similarity to the assembled sequence) and those with both structural variant breakpoints falling into gap regions (hg19). Each structural variant was required to have an assembled contig length of at least 10 bp on each breakpoint. CNAs in each tumour were integrated into the structural variant analysis by matching breakpoints within a 5-kb window to rescue rearrangements with CNA support by manual curation. A comparison of CGI structural variants with the known oncogenic re-arrangement in AML and B-ALL is presented in Supplementary Note 2. Copy number alterations. We adapted the CONSERTING algorithm 41 to detect CNAs from CGI WGS data. In brief, germline single nucleotide polymorphisms (SNPs) reported by CGI in Mutation Annotation Format files were extracted, and paralogous variants identified from 625 germline WGS cases generated by PCGP were removed. A coverage profile was constructed using the mean of SNP read counts within a sliding window of 100 bp, and the differences between tumour and normal samples were used as inputs for CONSERTING. To detect LOH, we used SNPs with variant allele fraction (VAF) in normal sample within an interval of (0.4, 0.6) and > 15× coverage in tumour and normal samples. Allelic imbalance (AI; | Tumour_VAF-0.5| ) was used to detect LOH. Regions with concomitant copy number changes (| log ratio| > 0.2) or LOH (AI > 0.1) were subjected to manual review. Finally, regions less than 2 Mb were considered focal and included in the GRIN 12 analysis to determine the significance of the somatic alterations. A comparison of our CNA detection with clinical information is provided in Supplementary Note 3.
For osteosarcomas, manual reviews of candidate genes affected by CNA were prioritized for the following three groups owing to the high number of rearrangements caused by chromothripsis in this histotype 42 : (1) gene expression change matched the CNA status; (2) genes with recurrent loss and gain; and (3) published osteosarcoma driver genes 42 . This resulted in the discovery of 13 focal CNAs affecting CCNE1, CDKN2A, RB1, PTEN, TUSC7, and YAP1 in addition to TP53. WES data analysis. Of the 1,131 tumour-normal WES pairs, all but 23 osteosarcoma pairs exhibited the expected binomial distribution of B-allele fraction for germline SNPs. The 23 outlier samples were therefore used neither for the discovery of driver genes nor for calculating mutation rate in coding regions (Fig. 1b) . They were included only for determining driver mutation prevalence.
Somatic SNVs and indels were detected by the Bambino 43 program, followed by postprocessing and manual curation as previously described 44, 45 . To address 8-oxo-G artefacts 35 , we implemented the D-ToxoG filtering algorithm 46 . Somatic mutation rate. The median mutation rate of 651 CGI WGS samples (Fig. 1a ) was calculated from tier3 non-coding SNVs 47 . This analysis did not include the T-ALL cohort as only three T-ALLs were analysed by the CGI platform. Mutations in coding regions were based on coding SNVs from 1,639 samples analysed by WGS or WES (Fig. 1b ). Among these, 120 samples were analysed by both WGS and WES, and the union of coding SNVs from WGS and WES were used. Twentythree osteosarcoma WES samples were excluded from coding mutation analysis owing to quality issues described in 'WES data analysis' . For osteosarcomas, the mutation rate in coding regions (0.53 per Mb) is lower than in non-coding regions (0.79 per Mb). Nineteen osteosarcoma samples were analysed by both CGI and WES. For these samples, the mutation rate in coding regions derived from either CGI or WES was 0.54 per Mb while the mutation rate in the non-coding regions was 0.79 per Mb, indicating a potential contribution of kataegis 42 in the elevated mutation rate in non-coding regions. Within each histotype, hypermutators were defined as having mutation rates 3 s.d. above the mean (trimming 5% outliers). Mutational signature analysis. Mutational catalogues were generated for each sample by using a 96-bin classification ( Supplementary Table 1b ). These were examined for all samples with our previously established methodology 48 to decipher mutational signatures and to quantify their activities in individual samples. The correlation between age of diagnosis and mutational signature activities was computed by using robust regression 49 . We also compared the cosine similarity between original and reconstructed samples and found that samples with more than 100 mutations had cosine similarities greater than 0.85, whereas samples with less than 100 mutations mostly (93.5%) had cosine similarities less than 0.85.
To calculate the average MAF values for each signature (Fig. 1e) , each of the 96 mutation types was assigned to the signature with the highest probability (the same result was obtained if we required the highest probability to be higher than the second (by Δ = 0.05, 0.1, and 0.2; data not shown). This assignment was also used for Extended Data Fig. 2e 
The two novel signatures, T-10 and T-11, were enriched in low MAF mutations. T-11 was the only signature that was significantly correlated (r 2 = 0.9) with the presence of multi-nucleotide variations composed of co-occurring SNVs separated by 3 or 4 bp which were not verified by Illumina WES. Therefore, it is likely to be associated with platform-specific sequencing artefacts.
For the eight B-ALL cases identified with mutation signatures of UV-light exposure, only 0.96% of the somatic SNVs overlap with SNPs that have population allele frequencies (AFs) > 0.1% in the gnomAD database (version r2.0.1; http:// gnomad.broadinstitute.org/). The overlap is only 0.22% if using AF > 1%. The overlap rate is comparable to the 1.1% observed for non-UV somatic SNVs across the entire cohort (0.27% match if using AF > 1%).
For each of these eight B-ALL cases, UV-and non-UV-mutations were stratified according to the ploidy of their genomic locations (Extended Data Fig. 2e -g; cluster centres estimated using R package mclust). Inter-mutational distances were plotted for comparison of genomic distribution of UV-versus non-UV mutations. Chromosomal ploidy and tumour purity were obtained from TARGET clinical files and prior publications 50 . By adjusting for ploidy and corresponding tumour purity, we calculated expected MAFs for clonal mutations as follows: denoting the tumour purity as π, the expected MAF for clonal mutations was π/(2 − π) in the 1-copy loss region, π/2 in the diploid region, and π/(2 + π) in the 1-copy gain (wild-type allele) region.
Age-specific incidence rates for childhood ALL reported by the Surveillance, Epidemiology, and End Results (SEER) program show that the rate of incidence Letter reSeArCH estimate tumour purity. For regions with LOH, a previously described method was used 42 . For SNVs, an unsupervised clustering analysis was performed with the R package mclust. Tumour purity was defined to be two times the highest cluster centre that was < 0.5. The maximal CNA and SNV purity was used.
We compared our estimates with blast counts for 197 AML and 9 B-ALL samples. Of the 135 tumours with blast count > 70% (value 'many' in clinical file was mapped as > 70%), we identified 127 (94%) with purities > 70% (seven of the other eight tumours had purities > 50%). An additional 40 tumours were estimated with purities > 70%, although their blast count was below 70%. Thirty-one tumours were classified as low purity (< 70%) by both our analysis and blast count. KRAS isoform analysis. We investigated alternative splicing in KRAS (Extended Data Fig. 6 ), as differential oncogenic activity of mutant alleles expressed in KRAS 4a or 4b isoforms has been reported previously 52 . We detected splice junction reads connecting exon 3 to one of the two novel acceptor sites in the last intron (53 bp apart). This aberrant splicing is predicted to create two novel isoforms, each incorporating one of the two novel exons (40 bp and 93 bp, respectively) located 2.2 kb downstream of exon 4A (Extended Data Fig. 6b ). These novel isoforms would form truncated KRAS proteins (154/150 amino acid), each retaining the GTPase domain but losing the hypervariable region that is critical for targeting KRAS to the plasma membrane 53 .
One of the two novel isoforms (novel isoform 2) was detected in myeloid cells from three healthy donors (data not shown). Protein products of KRAS isoforms in AML cells were analysed by western blot (Supplementary Notes 5, 6 ). RNA-seq data analysis. RNA-seq data were mapped with StrongArm 23 , and rearrangements identified with CICERO 23 , followed by manual review. We performed RNA-seq clustering to confirm the tissue of origin and analysed immune infiltration using ESTIMATE 54 and CIBERSORT 55 (Extended Data Fig. 7 , Supplementary Notes 7, 8) . Allele-specific expression (ASE) in RNA-seq. CGI and WES allele counts were combined whenever possible. Point mutations were required to have DNA and RNA coverage ≥ 20×. Variants with | RNA_MAF -DNA_MAF| > 0.2 and a false discovery rate of < 0.01 (calculated with R package qvalue 51 on two-sided Fisher's exact test P) were considered to show ASE. Within-sample analysis was performed to distinguish ASE from potential artefacts caused by normal-in-tumour contamination (Extended Data Fig. 8d , Supplementary Note 9, Supplementary Table 5 ). Single-cell targeted re-sequencing. One cryopreserved vial each from patients PAPWIU and PABLDZ was thawed using the ThawSTAR system (MedCision) and then diluted in RPMI supplemented with 1% BSA. The cells were then washed five times with C1 DNA-seq wash buffer according to the manufacturer's instructions (Fluidigm), counted and viability estimated using the LUNA-FL system (Logos Biosystems), then diluted to 300 cells per μ l and loaded in a small C1 DNA-seq chip according to the manufacturer's instructions (Fluidigm, except the suspension buffer to cell ratio was changed from 4:6 to 6:4). The cells also underwent an on-chip LIVE/DEAD viability stain (Thermo Fisher). Each capture site was imaged using a Leica inverted microscope and phase contrast images, as well as fluorescent images with GFP and Y3 filters, were acquired to determine the number of cells captured and the viability of each. The cells then underwent lysis, neutralization, and MDA WGA according to the manufacturer's instructions (Fluidigm) using the GenomePhiv2 MDA kit (GE Life Sciences). One C1 chip was run per patient. Selected variants and germline SNPs then underwent microfluidic PCR-based targeted resequencing in the bulk sample or genomes amplified from the single cells using the Access Array System as previously described 56 . Target-specific assays were designed using primer3plus (https://probes.pw.usda.gov/batchprimer3/) and employed oligos purchased from Integrated DNA Technologies; multiplexing was performed according to guidelines in the Access Array manual (Fluidigm). All samples were loaded with the Access Array loader and underwent PCR cycling in an FC1 system, followed by sample-specific barcoding using standard PCR, all according to the manufacturer's instructions (Fluidigm). Amplicons were run on the MiSeq using v2 chemistry with 2 × 150-bp paired-end reads (Illumina), using custom sequencing primers, according to the Access Array manual (Fluidigm). Single-cell sequencing data analysis. Mapped BAM files for each of the 96 single-cell assays were genotyped for all designed markers. Assays with two captured cells (6 assays for both cases) or assays with fewer than 50% of designed markers with coverage 10× or greater, were dropped, resulting in 48 assays for case PAPWIU (Supplementary Table 6 ) and 64 assays for case PAPEWB (Supplementary Table 7 ). The assays were called tumour cells if they had one or more somatic markers with MAFs greater than 0.05. Germline markers with MAFs greater than 0.05 were called positive. The R package pheatmap was used to visualize the single-cell data using hierarchical clustering with 'binary' distance and 'complete' agglomeration method. Code availability. Custom codes are available from the authors upon request.
Extended Data Figure 1 | Cohort description and workflow. a, Venn diagram of samples analysed by whole-exome (WES), whole genome (CGI) and whole transcriptome (RNA-seq) sequencing in this cohort. b, c, Sample-level sequencing status of the entire cohort (b) and those with WGS data (c, SNP6 for T-ALL). d, Age distribution for each histotype. Median, first and third quartiles are indicated by horizontal bars. Sample sizes are indicated in parentheses. Percentage of cases with age over 20 years are indicated. e, Analytical workflow. The tumour/normal BAM files of WES data were analysed by our in-house pipeline followed by manual quality control. The mutation annotation format files generated by CGI were downloaded from TARGET Data Matrix (see Methods) and analysed by a pipeline developed for this dataset, including SNVs, indels and structural variants. CAN and LOH were analysed using read counts of germline SNPs in the mutation annotation format files. Manual quality control was also performed. For RNA-seq data, the FASTQ files were re-mapped and fusions and ITDs were analysed with CICERO. The resultant mutations were analysed by GRIN (SNVs, indels, CNAs, structural variants and fusions) and MutSigCV (SNVs and indels) to discover 142 recurrently mutated genes. f, One representative sample with chromothripsis for each histotype. CNAs are shown in the inner circle, orange indicates copy gain and blue indicates copy loss. Intra-and interchromosomal rearrangements are shown as green and purple curves, respectively. 

Extended Data Figure 7 | Clustering analysis of tumour RNA-seq data and immune cell infiltration analysis. a, Clustering analysis was carried out for 739 primary tumours with RNA-seq data available. The top 1,000 most variable expressed genes were clustered using Ward's minimum variance method. Each disease is annotated as shown in the first row with colour indicated in the key. b, c, Immune cell infiltration in osteosarcomas and NBL. Macrophage M0 and M2 were the dominant immune cell populations observed in osteosarcoma tumours (b). T and B cells, followed by macrophages, were the major immune cell types observed in NBL tumours (c).
Extended Data Figure 8 | Analysis of allele-specific expression. a, Mutant allele and total read count for SMC6 D1069N in DNA and RNA of NBL case PAPZYP. This is to illustrate variants with suppressed mutant allele expression despite high DNA MAF and a high level of gene expression in RNA-seq. P value was calculated using two-sided Fisher's exact test. DNA coverage of the MYCN and SMC6 region indicating multiple segments with high amplification (estimated at 26 copies). Details of the last three exons (E26, E27 and E28) of SMC6 are shown with DNA structural variants highlighted by vertical red bars. The mutation SMC6 D1069N is present in a region disrupted by structural variants, which dissociate the last three exons from the rest of SMC6. The high DNA MAF was therefore within a gene fragment that could not be transcribed and the expressed reference allele was from the intact gene. b, Non-expressed truncating (black) and non-truncating (blue) mutations showed a similar (P = 0.52, two-sided Wilcoxon rank-sum test) median MAF (horizontal black lines). The number of SNVs in each category is shown in parentheses. c, Hot spot mutations exhibited elevated mutant allele expression. Each mutation is shown as an oval positioned by its DNA MAF (x axis) and RNA MAF (y axis). The read count in DNA and RNA is depicted by the radius along the x-axis and y-axis direction, respectively. Mutations on chromosome X are shown as dotted ovals. Read counts from CGI and WES were combined whenever possible. d, Within-sample analysis to evaluate the effect of normal cell contamination on ASE. Shown are two samples with hotspot SNVs (red dots in cases PAPEWB and PATPBS) and two samples with truncating mutations (red circles in cases PAJNJJ and PARBFJ), which had a sufficient number of expressed coding mutations. The purity of each tumour is indicated. Dots represent SNVs and circles represent indels. Smaller symbols indicate the presence of CNA or LOH. An asterisk indicates a significant difference in MAFs between DNA (x axis) and RNA (y axis), which requires a minimum MAF difference of 0.2 (dashed lines) and a two-sided Fisher's exact test P < 0.01 (exact P values indicated in each panel). A dot in case PAJNJJ with DNA MAF of 0.5 and RNA MAF of 1.0 is not significant owing to low coverage (2× ) in RNA-seq. In all four cases, within-sample concordance of DNA and RNA MAF for all except the ASE mutation suggest that normal cell contamination has a negligible effect on ASE. Each row represents one germline SNP and each column is a single cell. Three clusters (11p LOH, Other, and 11p diploid) were detected according to variant allele frequency, ranging from 0.0 (green) to 1.0 (red). The top two rows indicate the cell type (tumour or normal) and WT1 D447N mutation status. b, Variants within the WT1 locus are highlighted with a blue box. The cluster 'Other' matches the 11p LOH cluster within the WT1 locus as the samples in this cluster had mono-allelic genotypes at WT1, probably caused by a focal deletion. The cluster 'Other' could also be caused by chimeric cells. However, as all cells in this cluster have the same pattern matching, the 11p LOH clusters within the WT1 gene (the blue box in b represents the genomic location of chr11:32,410,002-32,461,785 and WT1 is located at chr11: 32, 409, 457, 081) . A WT1 focal deletion better explains the profile in 'Other' . c, All nine missense WT1 mutations with DNA and RNA data. The lowest RNA coverage is 16 for WT1 R445P in AML case PABLDZ. Five mutations exhibiting allele-specific expression mutations (two-sided Fisher's exact test P < 0.01; exact P values also listed for each mutation) are highlighted in blue (grey for P ≥ 0.01). AML case PABLDZ (WT1 R445P) had LOH at the WT1 locus; LOH was present in the predominant clone at the diagnosis and may mask the presence of ASE in a subclone. d, e, Two JAK2 mutations (R683S and D873N) were detected in B-ALL case PAPEWB, in which D873N showed ASE (DNA MAF is 3/38, RNA MAF is 28/74, Fisher's exact test P < 0.01). A singlecell sequencing experiment was designed to investigate whether the ASE could be attributed to subclonal CNA undetectable in the bulk tumour. d, The 27 germline SNPs in JAK2 locus were selected along with the two somatic JAK2 mutations and the other 46 somatic variants. e, Heat map of genotype clusters generated from the 64 assays (4 bulk and 60 single cells) passing single-cell sequencing quality control and the original CGI genotype data. The absence of a cluster of mono-allelic genotypes indicates the absence of 9p LOH, which in turn confirms ASE of D873N. Corresponding author(s): Jinghui Zhang Life Sciences Reporting Summary Nature Research wishes to improve the reproducibility of the work that we publish. This form is intended for publication with all accepted life science papers and provides structure for consistency and transparency in reporting. Every life science submission will use this form; some list items might not apply to an individual manuscript, but all fields must be completed for clarity.
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Experimental design 1. Sample size
Describe how sample size was determined.
We analyzed all genome and transcriptome data collected from diagnosis tumor samples available under the accession number cited in the Online Methods section, except two cases: one is a duplicated neuroblastoma case, and the other is an osteosarcoma case which was collected from a patient age > 40 yrs.
Data exclusions
Describe any data exclusions.
Besides the two cases excluded from the analysis as described above, WES data from another 23 osteosarcoma samples were included only for determining driver mutation prevalence but not other analyses (see section "Whole exome data analysis" of the Online Methods for details).
Replication
Describe the measures taken to verify the reproducibility of the experimental findings.
The western blot for KRAS novel isoforms shown in Extended Data Figure 6g and 6h were done in duplicates, with similar observations.
Randomization
Describe how samples/organisms/participants were allocated into experimental groups.
Not relevant. Patient samples were grouped by disease types in this analysis.
Blinding
Describe whether the investigators were blinded to group allocation during data collection and/or analysis.
The investigators were not blinded to group allocation during the analysis. Patient samples were grouped by disease types. Detailed comparison was carried out among different type of tumors.
Note: all in vivo studies must report how sample size was determined and whether blinding and randomization were used. 
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Software
Policy information about availability of computer code
Describe the software used to analyze the data in this study.
Public available softwares: bwa (v0.7.12) for WES data alignment; Bambino for SNV/Indel analysis from WES; GRIN, MuSiC (v0.1), MutSigCV (v1.4) for driver mutation analysis; HTSeq for expression analysis from RNA-seq; R packages (v3.3.2) for statistical analysis; ESTIMATE (v1.0.13) and CIBERSORT for immune infiltration estimation; HotNet2 for pathway analysis; Circos (v0.69) for circular genome visualization; ProteinPaint portal for genomic data visualization. In house tools: STRONGARM for RNA-seq data alignment; CICERO for fusion detection from RNA-seq; Medal Ceremony for mutation pathogenicity analysis; ad hoc perl scripts were used in filtering genomic variants from CGI dataset.
For manuscripts utilizing custom algorithms or software that are central to the paper but not yet described in the published literature, software must be made available to editors and reviewers upon request. We strongly encourage code deposition in a community repository (e.g. GitHub). Nature Methods guidance for providing algorithms and software for publication provides further information on this topic.
Materials and reagents
Policy information about availability of materials
Materials availability
Indicate whether there are restrictions on availability of unique materials or if these materials are only available for distribution by a third party.
No unique materials were used.
Antibodies
Describe the antibodies used and how they were validated for use in the system under study (i.e. assay and species). c. Report whether the cell lines were tested for mycoplasma contamination.
We tested the mycoplasma contamination on 293T cells using MycoAlert kit (Lonza) and the result is negative.
d. If any of the cell lines used are listed in the database of commonly misidentified cell lines maintained by ICLAC, provide a scientific rationale for their use.
No commonly misidentified cell lines were used.
